Minerva Neurosciences, Inc. (NERV)

$2.52

+0.02

(+0.8%)

Market is closed - opens 7 PM, 24 May 2024

Insights on Minerva Neurosciences, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.6% return, outperforming this stock by 130.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.9% return, outperforming this stock by 321.5%

Performance

  • $2.44
    $2.52
    $2.52
    downward going graph

    3.19%

    Downside

    Day's Volatility :3.19%

    Upside

    0.0%

    downward going graph
  • $2.29
    $13.49
    $2.52
    downward going graph

    9.13%

    Downside

    52 Weeks Volatility :83.02%

    Upside

    81.32%

    downward going graph

Returns

PeriodMinerva Neurosciences, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-62.94%
-2.0%
0.0%
6 Months
-50.49%
10.5%
0.0%
1 Year
-63.0%
12.2%
0.0%
3 Years
-89.6%
16.4%
-20.6%

Highlights

Market Capitalization
17.5M
Book Value
- $5.23
Earnings Per Share (EPS)
-4.43
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-29.94%
Return On Equity TTM
-675.09%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-16.8M
EBITDA
-24.4M
Diluted Eps TTM
-4.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.89
EPS Estimate Next Year
-3.6
EPS Estimate Current Quarter
-1.2
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Minerva Neurosciences, Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 177.78%

Current $2.52
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Minerva Neurosciences, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
0.0%
-50.49%
-63.0%
-89.6%
-94.13%
Moderna, Inc.
Moderna, Inc.
50.68%
108.88%
24.64%
-0.1%
651.31%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.17%
22.83%
32.98%
95.93%
213.72%
Novo Nordisk A/s
Novo Nordisk A/s
7.46%
28.56%
67.6%
231.87%
458.02%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.49%
27.69%
35.03%
113.43%
162.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
NA
NA
0.0
-1.89
-6.75
-0.3
NA
-5.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.22
46.22
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.06
29.06
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
Sell
$17.5M
-94.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$62.6B
651.31%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.4B
213.72%
29.07
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$598.1B
458.02%
46.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.5B
162.44%
29.06
39.46%

Institutional Holdings

  • Federated Hermes Inc

    19.32%
  • FMR Inc

    7.03%
  • Vanguard Group Inc

    2.93%
  • Renaissance Technologies Corp

    1.53%
  • BlackRock Inc

    1.04%
  • UBS O'Connor LLC

    0.92%

Company Information

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its

Organization
Minerva Neurosciences, Inc.
Employees
9
CEO
Dr. Remy Luthringer Ph.D.
Industry
Health Technology

FAQs